Drug Repurposing Still Hits a Wall Between Discovery and Patient Access
Drug repurposing has long carried a simple promise: if a medicine already exists, the path to clinical use should be faster, cheaper, and less risky than developing a new compound from scratch. A new scoping review in Pharmacy shows why that promise so often stalls before patients benefit. Across 73 articles drawn from PubMed and ScienceDirect, investigators mapped a dense set of scientific, clinical, regulatory, economic, and implementation barriers, with one obstacle rising above the rest: moving a repurposed candidate from encouraging data to real-world clinical translation.
The problem begins with evidence. A molecule may already have a known safety profile in one disease area, but once it enters a different therapeutic context, the old data rarely answer the questions clinicians actually need. New Phase II/III trials are often required to confirm efficacy, establish safety in the new population, and determine the right dose. In practice, the original label becomes only a starting point. Disease biology changes the drug’s behavior, and the dose that is tolerable in one setting may be too weak, too toxic, or simply irrelevant in another.
A single repurposed drug can look clinically elegant in the laboratory and still fail at the bedside.
New Disease Contexts Create Old-Fashioned Trial Problems
The review makes clear that repurposing is not a shortcut around trial science; it is a request to repeat it under different conditions. Oncology brings subgroup-dependent responses, where a drug may work in one molecularly defined population and fail in another. Anti-infective candidates confront resistance and penetration problems, meaning a compound can appear active on paper yet never reach the site of infection in sufficient concentration. Rare diseases raise a different kind of barrier altogether: data scarcity limits the ability to define endpoints, estimate effect size, or even build a feasible study.
These are not abstract methodological concerns. They determine whether a candidate can survive the transition from hypothesis to prescription. In oncology, a repurposed therapy may need biomarker stratification before it can show any signal at all. In infectious disease, tissue penetration and resistance patterns can erase apparent activity. In rare disease, the absence of robust natural history data can make even a well-designed trial hard to interpret. Each of those problems slows translation, but they do so in different ways, which is why one generic repurposing playbook rarely works.
Computational Screening Has Its Own Translational Bottleneck
Artificial intelligence and other computational approaches were presented as part of the repurposing ecosystem, but the review gives them no free pass. Fragmented data sets, limited model robustness, and insufficient validation remain central weaknesses. A predictive algorithm can point to a promising candidate, yet without reliable external validation, the result remains a suggestion rather than a clinical strategy. The underlying issue is familiar in medicine: a model is only as credible as the data feeding it, and repurposing often depends on literature, databases, and experimental results that were never built to answer the same question in the same way.
This creates a layered problem. Computational tools may accelerate hypothesis generation, but they do not eliminate the need for clinical confirmation. They can help prioritize candidates, identify molecular pathways, or expose unexpected drug-disease links, but they cannot replace human-led evaluation of efficacy, safety, drug-drug interactions, or dosing in the target population. The review treats this as a structural limitation, not a temporary inconvenience.
Off-Patent Drugs Face a Harsh Economic Equation
One of the strongest tensions in repurposing sits outside biology. Off-patent drugs often require evidence standards as rigorous as those applied to entirely new agents, yet they do not come with the market exclusivity that typically attracts private investment. That gap leaves many promising candidates stranded between academic proof-of-concept and commercial development. A medicine can be clinically useful and still fail to move forward if no sponsor sees a viable path to recoup trial costs, regulatory work, and manufacturing demands.
The economic barrier is especially sharp because repurposing is often assumed to be inexpensive simply because the molecule already exists. In reality, the expensive part is not synthesis; it is confirmation. Large trials, regulatory submissions, and label expansion all require capital. Without incentives, even well-supported candidates may never reach the stage where patients can receive them under formal indications.
Regulatory Pathways Remain Fragmented and Slow
Regulation emerges in the review as more than a paperwork hurdle. An institutional bottleneck limits how academic investigators move repurposed findings onto the label, largely because many research groups lack the regulatory infrastructure and collaborative networks needed to navigate approval pathways. This matters because repurposing often begins in universities, hospitals, and public research settings rather than in companies built to manage market authorization.
The result is an uneven pipeline. Academic teams may generate compelling early data, but without early regulatory engagement and coordinated partnerships, those findings can remain locked in publications instead of entering practice. The review argues for a distinct translational paradigm, one that treats regulatory planning as part of the discovery process rather than a final administrative step.
The access problem begins long before a prescription is written.
Why a Distinct Translational Model Is Needed
The review’s central message is direct: drug repurposing is not just a cheaper version of drug development. It is a different clinical and regulatory enterprise that needs its own workflow. Scientific validation, disease-specific trial design, reimbursement logic, and regulatory readiness all have to advance together if repurposed medicines are going to reach patients efficiently. Multi-stakeholder collaboration becomes essential because no single group controls the full chain from preclinical signal to approved use.
That has practical implications for clinicians, investigators, and policy makers. Clinicians need stronger evidence before adopting repurposed therapies outside their original indications. Researchers need trial designs that fit the disease context rather than the convenience of the candidate. Regulators need earlier engagement with academic developers. Funders and sponsors need pathways that reward confirmation work, not just discovery. Without those supports, even strong scientific leads can become stranded assets.
The review does not suggest that repurposing is unworkable. It shows that the field succeeds only when the usual shortcuts are replaced by deliberate infrastructure, disciplined validation, and realistic expectations about what it takes to bring an old drug into a new disease. The unresolved challenge is not whether repurposing can generate interesting signals in the lab; it is whether the medical system is prepared to build the pathway that turns those signals into approved, accessible treatment.